Abstract
Rationale Dysbiosis of the gut microbiome may augment lung disease via the gut-lung axis. Proteobacteria may increase MMP-9 release and contribute to tissue proteolysis followed by neutrophil recruitment, lung tissue injury, and perpetuation of chronic lung disease.
Trial Design We sought to determine if a Lactobacillus probiotic and herbal blend was safe and well-tolerated in healthy volunteers and asthmatic patients.
Methods We conducted a 1-month randomized, open-label clinical trial in Cork, Ireland with healthy and asthmatic patients who took the blend twice a day. The primary endpoint was safety with secondary endpoints including quality of life, lung function, gut microbiome ecology, and inflammatory biomarkers.
Results All subjects tolerated the blend without adverse events. Asthmatic subjects who took the blend showed significant improvements in lung function as measured by forced expiratory volume and serum short chain fatty acid levels from baseline to Week 4. The gut microbiome of asthmatic subjects differed significantly from controls, with the most prominent difference in the relative abundance of the proteobacteria Escherichia coli. Administration of the probiotic maintained overall microbial community architecture with the only significant difference being an increase in absolute abundance of the probiotic strains measured by strain-specific PCR.
Conclusions This study supports the safety and efficacy potential of a Lactobacillus probiotic plus herbal blend to act on the gut-lung axis.
ClinicalTrials.gov Identifier: NCT05173168
Competing Interest Statement
ResBiotic Nutrition Inc is a university startup out of the University of Alabama at Birmingham of which Dr. Lal is the Founder, Dr. Gaggar is the Chief Medical Officer, and Dr. Ambalavanan and Dr. Willis are Advisors.
Clinical Trial
NCT05173168
Funding Statement
Research reported in this article was supported by the National Heart, Lung and Blood Institute of the National Institutes of Health under award number K08 HL141652 (CVL) and K08 HL151907 (KAW). resB Lung Support for clinical trial use was gifted by ResBiotic Nutrition, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Clinical Research Ethics Committee of the Cork Teaching Hospitals of University College Cork gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact Information: Charitharth Vivek Lal, MD1, 1500 1st Ave N, Suite H102, Birmingham, AL 35203, Tel: 667-295-7372, Email: clal{at}uabmc.edu
Results section revised for clarity
Data Availability
The data that support the findings of this study are openly available in SRA at https://www.ncbi.nlm.nih.gov/bioproject/PRJNA922968, reference number PRJNA922968.
